Table 1.
Clinical characteristics of mixed response group
| MR–R (n = 36) | MR–NR (n = 22) | p value | |
|---|---|---|---|
| Median age | 67 (29–85) | 75 (48–85) | 0.03 |
| ECOG | |||
| < 1 | 28 (78) | 12 (55) | 0.06 |
| ≥ 1 | 8 (22) | 10 (45) | |
| Gender | |||
| Female | 10 (28) | 4 (18) | 0.53 |
| Male | 26 (72) | 18 (82) | |
| Location primary | |||
| Trunk | 8 (22) | 6 (27) | 0.55 |
| Lower ex | 9 (28) | 7 (32) | |
| Head/neck | 10 (28) | 3 (14) | |
| Penis | NA | 1 (5) | |
| Vulva/vaginal | 1 (3) | 2 (9) | |
| Unknown | 7 (19) | 3 (14) | |
| Tumor histology | |||
| SSM | 7 (19) | 5 (23) | 0.76 |
| Nodular | 9 (25) | 4 (18) | |
| Acral | NA | 1 (5) | |
| Mucosal | 1 (3) | NA | |
| Desmoplastic | 1 (3) | NA | |
| Unknown | 18 (50) | 12 (54) | |
| Ulceration | |||
| No | 12 (33) | 8 (36) | 0.99 |
| Yes | 13 (36) | 8 (36) | |
| Unknown | 11 (31) | 6 (27) | |
| Median Breslow (mm) | 4.1 (0.4–8.3) | 3.2 (0.7–42) | 0.64 |
| M stage | |||
| M1a | 5 (14) | 1 (5) | 0.39 |
| M1b | 11 (31) | 2 (9) | 0.1 |
| M1c | 12 (33) | 6 (27) | 0.77 |
| M1d | 7 (19) | 13 (59) | < 0.01 |
| No. sites mets | |||
| No | 25 (69) | 6 (27) | < 0.01 |
| Yes | 11 (31) | 16 (73) | |
| Mutational status | |||
| BRAF V600E/K | 14 (39) | 4 (18) | 0.05 |
| NRAS | 7 (19) | 8 (36) | 0.41 |
| WT | 7 (19) | 8 (36) | 0.53 |
| Not tested | 3 (8) | NA | 0.27 |
| Total mutations ≥ 5 | 7 (19) | 3 (14) | 0.48 |
| Median LDH | 183 (148–213) | 212 (190–247) | < 0.01 |
MR–R mixed response to response, MR–NR mixed response to non-response, ECOG Eastern Cooperative Oncology Group, SSM sustained mixed response, BRAF V600E/K B-Raf proto-oncogene V600E/K mutation, NRAS NRAS proto-oncogene, WT wild type, LDH lactate dehydrogenase
Bold values indicate p < 0.05
Patients with a subsequent response tended to be younger (p = 0.03), were less likely to have M1d disease (p < 0.01), had fewer that 3 sites of metastases (p < 0.01), were more likely to have a BRAF V600E/K mutation (p = 0.05), and were less likely to have an elevated LDH (p < 0.01)